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Tujuan studi ini adalah untuk menjelaskan mekanisme resistensi parasit malaria dan 
usaha-usaha yang dapat dilakukan untuk menghadapi munculnya strain parasit yang 
resisten terhadap artemisinin. Metode yang digunakan adalah studi kepustakaan. Resistensi 
P.falciparum terhadap obat-obat anti malaria disebabkan oleh perubahan spontan yang 
terjadi pada beberapa gen seperti P.falciparum multi drug resistance1 (Pfmdr1), P.falciparum 
chloroquine transporter (Pfcrt), P.falciparum dihydropteroate synthase (Pfdhps), P.falciparum 
dihydrofolate reductase (Pfdhfr), and P.falciparum multidrug resistance-associated proteins 
(Pfmrp). Penyebaran resistensi tersebut dipengaruhi oleh tingkat transmisi di sebuah wilayah. 
WHO telah menjalankan usaha untuk menanggulangi penyebaran resistensi tersebut misalnya 
dengan merekomendasikan penghentian monoterapi artemisinin, dan pemberian anti malaria 
setelah konfirmasi laboratorium. Selain itu, perlu adanya penggunaan obat kombinasi, produksi 
rejimen dosis tetap, dan pengembangan obat anti malaria baru. Kesimpulan dari hasil studi 
ini ialah munculnya malaria resisten terhadap artemisinin akan menghambat usaha eradikasi 
malaria karena itu diperlukan usaha-usaha untuk menanggulanginya.
Kata kunci: resistensi obat anti-malaria, artemisinin-combination therapy (ACT), malaria 
resisten artemisinin, Plasmodium falciparum
Abstract
The objective of this study was to describe the development of anti-malarial drug resistance 
of the parasites and the efforts taken to contain the emergence of artemisinin resistant malaria. 
This was a literature study. The development of resistance to anti-malarial drugs are due to 
spontaneous changes in certain genes such as of P.falciparum multi drug resistance1 (Pfmdr1), 
P.falciparum chloroquine resistance transporter (Pfcrt), P.falciparum dihydropteroate synthase 
(Pfdhps), P.falciparum dihydrofolate reductase (Pfdhfr), and P.falciparum multidrug resistance-
associated proteins (Pfmrp). The spread of the resistance depends on the transmission rate 
within each area. WHO has established a global plan to contain the spread of this resistance, 
such as recommendation to withdraw artemisinin-based monotherapies and  administration 
of treatment after laboratory confirmation. In addition, administration of anti-malarial drug 
combination, production of fixed dose regimen and development of new drugs are necessary. 
The Conclusion is emergence of artemisinin resistant malaria will threaten malaria eradication 
thus some efforts are necessarily needed to contain it.
Keywords:  anti-malarial drug resistance, artemisinin-combination therapy (ACT), artemisinin 
resistant malaria, Plasmodium falciparum
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INTRODUCTION
Malaria is still one of major infectious 
diseases nowadays, especially in Sub Sa-
haran Africa where most deaths of the 
disease occur. It is caused by the parasite 
Plasmodium spp and transmitted by female 
Anopheles mosquitoes. There are currently 
five species known to cause malaria in human; 
Plasmodium falciparum, Plasmodium vivax, 
Plasmodium ovale, Plasmodium malariae 
and Plasmodium knowlesi. 
Development of anti-malarial drugs to 
treat the disease has reduced morbidity and 
mortality due to malaria. WHO has achieved 
a very good progress in eliminating malaria, 
as 43 countries reported a more than 50 % 
reduction in the number of malaria cases in 
10 years, between 2010 and 2000.1 Globally, 
the number of malaria cases has reduced 
17% in 2010 since 2000. These achievements 
are due to comprehensive ongoing efforts 
undertaken by WHO in eliminating the 
disease through several projects. However, 
the ability of the parasites to adapt with the 
drugs and eventually develop resistance will 
threaten WHO malaria eradication program. 
First line therapy for malaria has shifted 
several times due to antimalarial drug 
resistance development of the parasites. 
From 1632 until 1900, the only drug used to 
treat malaria is quinine, which was derived 
from the bark of the cinchona tree and used 
to treat fever in Peru.2,3 Nowadays, it is still 
the drug of choice to treat severe falciparum 
malaria.4
In 1934 chloroquine, a derivative of 
quinine, was produced and then became 
first line therapy of malaria for years.3 
Unfortunately, since 1957, resistant parasites 
to the drug started to emerge from four 
different foci, namely The Thai-Cambodian 
border region in South-east Asia, Venezuela, 
Magdalena valley in Colombia, and Port 
Moresby in Papua New Guinea (PNG), which 
gradually spread throughout the world.3,5 
Although resistant parasites were also found 
in Africa in 1978, the strain was actually 
similar to that in South-East Asia, leading to 
the conclusion that the parasite resistance 
spread from South-east Asia to Africa.3  Due 
to the emergence of chloroquine resistant 
parasites, some countries considered to 
replace its deployment as the first line therapy 
of malaria. Thailand initiated this step in 
1973, followed by some other countries, until 
1988 when African countries also started to 
replace chloroquine.3
After the era of chloroquine deployment, 
a combination of two anti-folate drugs, 
sulphadoxine-pyrimethamine, known as 
Fansidar®, became the drug of choice for 
malaria treatment in some regions.6 Besides, 
proguanil, another anti-folate drug, became 
the most potent prophylaxis. In contrast with 
the development of resistance to chloroquine 
which took more than 20 years, the resis-
tance to proguanil and pyrimethamine devel-
oped promptly after its deployment in some 
areas.3 Pyrimethamine resistance was firstly 
reported in 1967 in Thailand, soon after it 
was introduced in the same year.
On the other hand, some areas in 
Thailand started to use mefloquine replacing 
chloroquine in 1973, and the government 
officially recommended it as the drug of 
choice in 1984. Unfortunately, in 1990, the 
resistance to this drug started to emerge.7
In November 1999, a new venture 
called The Medicines for Malaria Venture 
(MMV) was established by WHO and 
some pharmaceutical industries in order to 
develop new anti-malarial drugs, including 
artemisinin (qinghaosu) derivatives which 
were isolated from the Chinese wormwood, 
Artemisia annua.8 There are three different 
compounds have been developed, namely 
artemisinin, artesunate, and artemether. 
Currently artemisinin and its derivatives are 
considered as the most potent drugs to treat 
malaria and is used as the first line therapy 
as recommended by WHO.1 Yet, some recent 
studies conducted in the Thai-Cambodia 
border region suggested that artemisinin 
resistant strain of P. falciparum has emerged 
in that area.9
Considering the occurence of resistance 
to anti malarial drugs as described above, it 
is important to understand the mechanism 
of the development of drug resistance of 
the parasites, especially P. falciparum which 
can cause the most severe form of malaria 
known as cerebral malaria, and to identify 
the factors that attribute to increase the risk 
of the emergence of resistant strains. Thus, 
the aim of this paper is to describe those 
mechanism and  the key attributes of the 
resistance development. In addition, some 
efforts which are necessary to  contain the 
spread or the emergence of artemisinin 
resistance parasites will be discussed.
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METHODS
This essay is done by searching and 
reviewing several studies regarding anti-
malarial drug resistance of P. falciparum. 
RESULTS AND DISCUSSION
It is suggested that a spontaneous 
genetic change, either a point mutation 
or multiplication of certain genes in the 
parasite is the major source of resistance 
to anti-malarial drugs.7The number of mu-
tated genes involved in the mechanism of 
resistance and the half-life of drugs affect the 
time period needed to the emergence of a 
resistant strain.3 Whether a single or multiple 
mutations required for the development of 
the resistance depends on the administered 
drugs.10 The resistance to anti-malarial drugs 
are more commonly observed in P.falciparum 
than the other Plasmodium species.3
Chloroquine resistance developed after 
several mutations in the parasite genes.5 A 
number of genes involved in the mechanism 
of resistance to this drug, namely P.falciparum 
chloroquine transporter (Pcrt); P. falciparum 
multidrug resistance 1 (Pfmdr1), P. falciparum 
multidrug resistance-associated proteins 
(Pfmrp), and P. falciparum Na+/H+ exchanger 
(Pfnhe).11
Pfcrt which is located in the chromosome 
7 encodes a trans-membrane protein in the 
parasite digestive vacuole (DV).11 In the DV, 
the haemoglobin digestion products are 
polymerized by chloroquine, producing toxic 
haem which kills the parasite.8 It was found that 
parasites with a lysine to threonine mutation 
at codon 76 (K76T ) in Pfcrt accumulate less 
chloroquine in the DV compared to those 
without such mutation.11 In the resistant 
strains, less accumulation of chloroquine is 
due to drug efflux or reduced uptake.8It is 
because mutant parasites undergo a change 
in the DV membrane from being positively 
charged to being uncharged, allowing the di-
protonated drugs being actively transported 
out from the vacuole.11
Meanwhile, Pfmdr1 which is located in 
the chromosome 5 encodes an ATP-binding 
cassette (ABC) protein which, similar to Pfcrt, 
also exists in the DV membrane.11 Mutations 
in several amino acid positions in this gene 
decrease the accumulation of some anti-
malarial drugs such as chloroquine, quinine, 
mefloquine, artemisinin, lumefantrine, and 
halofantrine, and increase the drug efflux.11 
Some studies have identified the positions 
of mutations in the gene that might confer 
resistance in the parasite, such as asparagine 
to tyrosine mutation at codon 86 (N86Y), 
serine to cysteine at codon 1034 (S1034C), 
asparagine to aspartic acid at codon 1042 
(N1042D), and aspartic acid to tyrosine at 
codon 1246 (D1246Y).12
Besides, Pfmrp, which is located on 
chromosome 1, encodes a protein that 
is located in the plasma membrane and 
membrane-bound vesicles of the erythrocytic 
stages of the parasite.11 In contrast with 
mutations of Pfcrt and Pfmdr1 which cause 
decrease susceptibility of the parasite to anti-
malarial drugs, mutation in Pfmrp results in 
an increase anti-malarial susceptibility of the 
parasites.11
On the other hand, the parasite might 
confer resistance to anti-folate drugs such 
as sulphadoxine-pyrimethamine when point 
mutations occur in some genes involved in 
folate pathway, namelyP. falciparum DHPS 
(Pfdhps) and P. falciparum (Pfdhfr),because 
anti-folate drugs act by inhibiting the en-
zymes used in the folate synthesis such 
as dihydropteroate synthase (DHPS) and 
dihydrofolatereductase (HFR).10,11DHPS is 
inhibited by sulfonamide, while DHFR is in-
hibited by pyrimethamine.10
Finally, even though it has been 
suggested that artemisinin resistance para-
sites might have emerged, the mechanism 
of the resistance to this drug is still unclear.1 
Some studies have been conducted focusing 
on several mutations that occur in the genes 
that involved in chloroquine resistance, but 
none has proposed the true mechanism of 
artemisinin resistance.11
In addition to spontaneous mutations, 
it was proposed that the resistance to 
certain anti-malarial drugs are influenced by 
several other factors, such as mutation rate, 
high parasite load, the strength of the drug 
selection, and the treatment compliance. 
Exposure to sub-optimal drug concentration 
due to inappropriate dose, fake or counterfeit 
drugs, and reinfection during anti-malarial 
elimination phase, which commonly occur in 
high-transmission areas, also attribute to the 
emergence of resistance.11
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Geographical difference in the emergence 
of resistant parasites
As mentioned before, choloroquine 
resistant parasites emerged from four 
different foci, 2 in south America, 1 in South 
East Asia, and 1 in Papua New Guinea.3,5 
This was concluded from the result of 
molecular analysis of the parasite resistant 
strains in those foci.5 Although most malaria 
deaths occur in Africa, there is no original 
chloroquine resistance from this region.5
Parasites that confer mutations do 
not always survive, depending on the local 
epidemiology of the disease, such as the 
transmission rate of mutated parasites and 
their selective advantage.5 In addition, the 
risk of increased drug pressure depends 
on the treatment seeking behavior of the 
infected patients which is influenced by their 
immunity to the infecting agents.7 Hence, 
the difference in the intensity of parasite 
transmissions causing different immune 
responses of population in each area 
results in different geographical distribution 
of anti-malarial resistant parasites.7In a low 
transmission area, such as South East Asia, 
selective mutations leading to resistance to 
anti-malarial drugs are more likely to occur 
and disseminate since most of the population 
are non-immune, and consequently most 
infections are symptomatic and require 
treatments.5 On the contrary, in the areas with 
high transmission rate such as in Africa, most 
of the population have developed immunity, 
resulting in asymptomatic disease and less 
drug deployment.5,7
However, in high transmission areas, 
drug pressure might be higher when 
infected patients take anti-malarial drugs 
with long half-lives, which can remain 
in sub-therapeutic level in the blood for 
weeks.7 Those people are more likely to 
get a re-infection, thus the newly infecting 
parasite is more likely to be exposed to the 
remaining low level of drugs, increasing the 
drug pressure. In addition, transmission of 
mutant parasites may occur more easily in 
high transmission areas because when an 
anti-malarial drug is administered, sensitive 
parasites will be killed but the resistant ones 
are not.7 Therefore, instead of transmitting 
the sensitive strains, mosquitoes will only 
transmit the mutant parasites.
Pharmacological development to contain 
anti-malarial resistant parasites 
It is very important to identify the 
efforts that can be undertaken to contain 
the resistance to anti-malarial drugs. Some 
strategies that have been done are reducing 
monotherapies, deploying drug combination 
therapies, administration of antimalarial 
drugs after laboratory confirmations, and 
developing some new drugs.
It has been suggested that mono-ther-
apy may induce resistance in the parasites 
more rapidly compared to combined drugs, 
as observed in a rapid atovaquone resis-
tance development when the drug is used as 
monotherapy, yet the resistance developed 
more slowly when it is used in combination 
with other drugs, such as tetracycline or pro-
guanil.10 Thus, one effort to contain the emer-
gence of anti-malarial resistance is withdraw-
ing the available monotherapy regimen, par-
ticularly artemisinin monotherapy that are still 
produced and marketed in some countries.1,8
In addition, as suggested by Professor 
Wallace Peters, drug combinations should 
be used for malaria treatment.8 Therefore, 
the current first line therapy is artemisinin 
combination therapy (ACT) which consists 
of artemisinin derivatives and a partner 
drug with longer half-life and different 
pharmacodynamic.1,13 Another alternative of 
anti-malarial drug combination is quinine with 
tetracycline or doxycycline as the second line 
therapy in some countries.13
Moreover, it is assumed that using 
non-fixed combination of anti-malarial drugs 
will reduce patient adherence to the drugs, 
resulting in an increased risk of resistance 
development of the parasites compared to 
using fixed-dose combinations.7 Therefore, 
at present, some fixed co-formulated 
combinations of anti-malarial drugs are being 
developed, such as Co-Artem®, consisting 
of artemether-lumefantrine, Artekin®, 
consisting of dihydroartemisinin and 
piperaquine, and Amonate FDC®, consisting 
of artesunate-amodiaquine.7,14
Furthermore, responding to the report 
of the emergence of artemisinin resistance 
emergence in the Greater Mekong region, 
South East Asia, WHO has established 
the global plan for artemisinin resistance 
containment (GPRAC) in 2011. This includes 
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conducting drug efficacy monitoring in every 
malaria endemic countries every 24 months, 
and elimination of counterfeit or substandard 
anti-malarial drugs.1
Another very important effort is to avoid 
administration of anti-malarial drugs before 
laboratory confirmation either by microscopy 
examination or rapid diagnostic test 
(RDT).1The administration of anti-malarial 
drugs in non-infected patients may increase 
the risk of resistance developmen.  
Finally, Medicines for Malaria Venture 
(MMV) has provided funding and research for 
new drugs development for uncomplicated 
malaria treatment which are efficacious to 
combat the resistant strains, with single dose 
administration and short term duration. There 
are three strategies used in this project, 
namely re-designing existing drugs, using 
older drugs in new ways, and targeting new 
specific sites in the parasite. Currently there 
are 9 undergoing projects which is being 
tested in clinical trials, and 12 projects in 
exploratory phase.15
One of the drug combinations that are 
currently being studied is chloroproguanil 
and dapsone.8 Chloroproguanil-dapsone 
(Lapdap)-artesunate acts against DHFR and 
DHPS, thus might be effective to combat 
sulphadoxine-pyrimethamine resistant para-
sites. Besides, combinations of artemisinin 
derivatives with some drugs that have been 
used as monotherapy for almost 20 years 
in China as malaria treatment such as pyro-
naridine and piperaquine are currently devel-
oped. Those combinations include pyronar-
idine-artesunate and piperaquine-dihydroar-
temisinin.
Other drugs being developed include 
synthetic endoperoxide based drugs, such 
as OZ277, which has been proven clinically 
effective in mice with unclear mechanism 
of action, pyridines, a new drug targeting 
the destruction of the parasite mitochondria 
resulting in the parasite cell death,  and 
DB289, an analogue of pentamidine which 
has been proven to be effective in a phase I 
trial to treat malaria in a 3 day course therapy 
with single dose.15
Besides that, studies to improve the 
effectiveness of some drugs that have been 
proven to be effective such as Co-Artem and 
amodiaquine are also being done. These 
include development of a powder paediatric 
regimen of Co-Artem to improve treatment 
for infants and children and a modification of 
amodiaquine known as isoquine to reduce 
the amodiaquine toxicity, without affecting 
its efficacy in treating chloroquine resistant 
parasites.15
CONCLUSION
The first line anti-malarial drug has 
been changed several times due to the ability 
of malarial parasite to develop resistance to 
the drug. Resistance occur as a result of 
genetic changes in the parasite due to point 
mutation or multiplication of certain genes. 
The resistance spread and occurrence in 
every region could be different depending 
on the parasite transmission rate. Since 
the emergence of the resistant parasites 
has been a major threat to WHO malaria 
eliminating program, some pharmacological 
development are currently being undertaken, 
such as administration of anti-malarial drug 
combination, production of fixed dose anti-
malarial regimen, and development of new 
drugs.
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